newsfilter
← Latest News
Business Wire·

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35